Abstract
Objectives:
The study aim is to describe interest in breast cancer chemoprevention among older women without a history of breast cancer and to determine whether aging-related factors such as diminished life expectancy, increasing comorbidity and medication burden attenuate chemoprevention interest.
Design:
Cross-sectional survey.
Setting:
University of Pennsylvania Health System.
Participants:
Four-hundred fifty-seven community-dwelling women aged 60–65 years old who were potentially eligible for breast cancer chemoprevention according to guidelines linking risk and eligibility to age.
Measurements:
Interest in breast cancer chemoprevention, Gail model breast cancer risk, perceived breast cancer risk, breast cancer worry, self-reported health status and comorbidities, and self-reported perceived life expectancy.
Results:
Of 457 participants, 11.2% reported being interested in taking chemoprevention, 40.9% reported no interest, and 47.9% reported being unsure about their interest in chemoprevention. Overall, interest in chemoprevention was not associated with individual Gail model breast cancer risk. In adjusted analysis, lack of interest among high-risk women was associated with low breast cancer worry and low perceived risk. Conversely, interest in chemoprevention among low risk women was associated with greater breast cancer worry. Age-related factors hypothesized to affect chemoprevention interest, including subjective life expectancy, increased comorbidity, and number of daily medications did not attenuate chemoprevention interest.
Conclusion:
Breast cancer worry and perceived breast cancer risk contribute to the lack of correlation between interest in breast cancer chemoprevention and objective breast cancer risk. Perceived life expectancy, increased comorbidity, and medication burden do not attenuate chemoprevention interest among older women.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA 295:2727–2741
Vogel V (2005) Chemoprevention in breast cancer. Clin Adv Hematol Oncol 3:531–533
Kinsinger LS, Harris R, Woolf SH et al (2002) Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:59–69
Chlebowski RT, Collyar DE, Somerfield MR et al (1999) American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clinl Oncol 17:1939–1955
Levine M, Moutquin JM, Walton R et al (2001) Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative’s Steering Committee on clinical practice guidelines for the care and treatment of breast cancer. CMAJ 164:1681–1690
Lewis CL, Kistler CE, Amick HR et al (2006) Older adults’ attitudes about continuing cancer screening later in life: a pilot study interviewing residents of two continuing care communities. BMC Geriatr 6:10
Kistler CE, Lewis CL, Amick HR et al (2006) Older adults’ beliefs about physician-estimated life expectancy: a cross-sectional survey. BMC Fam Prac 7:9
Bynum JPW, Braunstein JB, Sharkey P et al (2005). The influence of health status, age, and race on screening mammography in elderly women. Arch Intern Med 165:2083–2088
Mah Z, Bryant H (1992) Age as a factor in breast cancer knowledge, attitudes and screening behaviour. CMAJ 146:2167–2174
Black WC, Nease RF Jr., Tosteson AN (1995) Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 87:720–731
Smith BL, Gadd MA, Lawler C et al (1996) Perception of breast cancer risk among women in breast center and primary care settings: correlation with age and family history of breast cancer. Surgery 120:297–303
Bastian L, Lipkus I, Kuchibhatia M et al (2001) Women’s interest in chemoprevention for breast cancer. Arch Intern Med 161:1639–1644
Gail MH, Costantino JP, Bryant J, et al (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846
Doshi JA, Brandt N, Stuart B (2004) The impact of drug coverage on COX-2 inhibitor use in medicare. Health Aff Jan–Jun; Suppl Web Exclusives:W4-94-105
Remington P, Smith M, Williamson D et al (1998) Design, characteristics, and usefulness of state-based behavioral risk factor surveillance: 1981–87. Public Health Rep 103:366–375
Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886
Lerman C, Trock B, Rimer BK et al (1991) Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 114:657–661
Lerman C, Trock B, Rimer BK et al (1991) Psychological side effects of breast cancer screening. Health Psychol 10:259–267
Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388
Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101
Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93–97
Kiefe C, Funkhouse E, Fouad M et al (1998) Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med 13:357–365
Diefenbach M, Miller S, Daly M (1999) Specific worry about breast cancer predicts mammography use in women at risk for breast and ovarian cancer. Health Psychol 18:532–536
McCaul K, Branstetter A, Schroeder D et al (1996) What is the relationship between breast cancer risk and mammography screening? A meta-analytic review. Health Psychol 15:423–429
Bondy ML, Newman LA (2003) Breast cancer risk assessment models: applicability to African-American women. Cancer 97(1 Suppl):230–235
Greenlee RT, Hill-Harmon MB, Murray T (2001) Cancer Statistics, 2001. CA Cancer J Clin 51:15–36
Yancik R, Wesley M, Ries L et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885–892
Stefanick ML (2006) Risk-benefit profiles of raloxifene for women. N Engl J Med 355:190–192
Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137
Gradishar WJ, Cella D (2006) Selective estrogen receptor modulators and prevention of invasive breast cancer. JAMA 295:2784–2786
Mulley AG, Sepucha K. (2002) Making good decisions about breast cancer chemoprevention. Ann Intern Med 137:52–54
Acknowledgements
The authors would like to thank Rebecca A. Silliman and Jane L. Givens for valuable comments on earlier drafts of this manuscript.
This work was supported by a University of Pennsylvania FOCUS Clinical Investigator Award for Research in Women’s Health. Dr. Tjia was supported by a National Institute of Aging Grant K08 AG021527. Ms. Micco and Dr. Armstrong were supported by a National Cancer Institute Grant 1-RO1-HG02689-01.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Rights and permissions
About this article
Cite this article
Tjia, J., Micco, E. & Armstrong, K. Interest in breast cancer chemoprevention among older women. Breast Cancer Res Treat 108, 435–453 (2008). https://doi.org/10.1007/s10549-007-9614-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9614-8